Perhexiline is a carnitine palmitoyltransferase 1 (CPT1) and CPT2 inhibitor that was originally developed as an anti-anginal drug in the 1970s. It inhibits rat heart and liver CPT1 (IC50 = 77 and 148 μM, respectively) and rat heart CPT2 (IC50 = 79 μM). Inhibition of CPT reduces uptake of long-chain fatty acids into the mitochondria, thereby shifting cellular metabolism from β-oxidation to glycolysis. Perhexilin inhibits mTORC1 signaling at 10 μM and induces autophagy ~7-fold at a concentration of 10 μM in MCF-7 cells.
Pexid, Merrell-Tourade ,France ,1973
PERHEXILINE MALEATE SALT is a Vasodilator, used in treatments for angina.
Perhexiline maleate salt has been used to block fatty acid oxidation. It has also been used as 5′?adenosine?monophosphate-activated?protein kinase?(AMPK)?activator and in worm lifespan assay.
1,1-Dicyclohexyl-2-(2'-pyridyl)ethanol hydrochloride (5 grams) was dehydrated by heating with 25 ml of concentrated hydrochloric acid at steam bath temperature for 10 minutes. 70 ml of water were added to the reaction mixture to give the crystalline hydrochloride salt. The product, 1,1dicyclohexyl-2-(2'-pyridyl)ethylene hydrochloride, was recrystallized from methanol-ethyl acetate to yield a white solid melting at 150°-151.5°C.
1,1-Dicyclohexyl-2-(2'-pyridyl)ethylene hydrochloride (15 grams) in 150 ml of ethanol was hydrogenated in the presence of platinum oxide at about 60 pounds per square inch of hydrogen pressure. The product, 1,1-dicyclohexyl2-(2'-piperidyl)ethane hydrochloride, crystallized from a mixture of methanol and methyl ethyl ketone as a white solid melting at 243° to 245.5°C.
The hydrochloride salt was neutralized with 10% sodium hydroxide solution and the free base so produced was dissolved in ether. The ether solution was dried over anhydrous magnesium sulfate. Addition of an excess of maleic acid in methanol to the solution yielded the acid maleate salt which melted at 188.5°-191°C.
The starting material was obtained by reacting ethyl formate with cyclohexylmagnesium bromide to give dicyclohexylcarbinol. That is oxidized to dicyclohexylketone and then reacted with α-picoline.
Pexid (Marion Merrell Dow).
Perhexiline maleate regulates?coronary vasodilatation and blocks exercise-induced tachycardia. It is used to treat angina pectoris and variant angina. Perhexiline maleate functions as a cardiac metabolic agent. It is associated with peripheral neuropathy, high intracranial pressure with?papilledema?and proximal myopathy.
Perhexiline maleate is an anti-anginal metabolic modulator. It inhibits the mitochondrial enzyme carnitine palmitoyltransferase CPT-1 and to a lesser extent CPT-2. This causes a shift in myocardial substrate utilisation from long chain fatty acids to carbohydrates, resulting in increased glucose and lactate utilization and increased ATP production for the same O2 consumption as before and consequently increases myocardial efficiency. Perhexiline maleate was also recently found to inhibit the activity of mTORC1.
Poison by intraperitoneal route. Moderately toxic by ingestion.Human systemic effects by ingestion: muscle weakness, paresthesia, and hepatitis. Mutation data reported. Whenheated to decomposition it emits toxic fumes of NOx.
perhexiline maleate concentration-dependently and competitively inhibited cpt1 in rat cardiac and hepatic mitochondria, with an ic50 value of 77 and 148 μm, respectively. it was indicated that perhexiline maleate displayed a greater sensitivity of the cardiac than the hepatic enzyme when exhibiting inhibition effect [1]. perhexiline maleate produced concentration-dependent inhibition of cpt2 activity with an ic50 value of 79 μm [2]. in human breast cancer mcf-7 cells, perhexiline maleate blocked mtorc1 signaling at 10 μm and elicited autophagy ~7-fold at a concentration of 10 μm [3].
adult mice of swiss nmri strain were orally administrated with perhexiline maleate at a dosage of 100 mg/kg body weight/day for 10 weeks. perhexiline maleate triggered changes in nerve, including a few cytoplasmic inclusions in schwann and perineurial cells of mice treated with perhexiline maleate. after 11 weeks of administration of the drug, and up to 18 weeks, small abnormal zones were displayed on several muscle fibers, which were formed by tubular aggregates [4].
[1]. kennedy, j., unger, s., & horowitz, j. inhibition of carnitine palmitoyltransferase-1 in rat heart and liver by perhexiline and amiodarone. biochemical pharmacology. 1996; 52(2): 273-280.
[2]. kennedy, j., kiosoglous, a., murphy, g., pelle, m., & horowitz, j. effect of perhexiline and oxfenicine on myocardial function and metabolism during low-flow ischemia/reperfusion in the isolated rat heart. journal of cardiovascular pharmacology. 2000; 36(6): 794-801.
[3]. balgi, a., fonseca, b., donohue, e., tsang, t., lajoie, p., & proud, c. et al. screen for chemical modulators of autophagy reveals novel therapeutic inhibitors of mtorc1 signaling. plos one. 2009; 4(9): e7124.
[4]. fardeau, m., tomé, f., & simon, p. muscle and nerve changes induced by perhexiline maleate in man and mice. muscle & nerve. 1979; 2(1): 24-36.
